These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20729256)

  • 101. Images in clinical medicine. Baló's concentric sclerosis.
    Wengert O; Siebert E
    N Engl J Med; 2011 Aug; 365(8):742. PubMed ID: 21864168
    [No Abstract]   [Full Text] [Related]  

  • 102. A useful annual review of cognition in relapsing MS is beyond most neurologists - Commentary.
    Hutchinson M
    Mult Scler; 2016 May; 22(6):730-2. PubMed ID: 27048309
    [No Abstract]   [Full Text] [Related]  

  • 103. The relevance of cortical lesions in patients with multiple sclerosis.
    Geisseler O; Pflugshaupt T; Bezzola L; Reuter K; Weller D; Schuknecht B; Brugger P; Linnebank M
    BMC Neurol; 2016 Oct; 16(1):204. PubMed ID: 27769199
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Ecological impact of isolated cognitive relapses in MS.
    Meli R; Roccatagliata L; Capello E; Bruschi N; Uccelli A; Mancardi G; Inglese M; Pardini M
    Mult Scler; 2020 Jan; 26(1):114-117. PubMed ID: 30430928
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Evaluation of cognitive dysfunction by the clock drawing test in multiple sclerosis and clinically isolated syndrome patients: Correlation with other neuropsychological tests.
    Tekin S; Bir LS; Oncel C; Unluturk Z; Aydın E
    Neurosciences (Riyadh); 2022 Oct; 27(4):251-256. PubMed ID: 36252970
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis.
    Boa INF; Rimkus CM; Campanholo KR; Pereira SLA; Junqueira TF; Machado MAR; Callegaro D; Otaduy MCG; Leite CDC; Miotto EC
    Arq Neuropsiquiatr; 2018 May; 76(5):302-309. PubMed ID: 29898076
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Relapsing-remitting tumefactive multiple sclerosis.
    Selkirk SM; Shi J
    Mult Scler; 2005 Dec; 11(6):731-4. PubMed ID: 16320737
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Significance of the Diagnosis of Executive Functions in Patients with Relapsing-Remitting Multiple Sclerosis.
    Borkowska AR; Daniluk B; Adamczyk K
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639827
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Differentiation of Cognitive Deficit Profiles in Multiple Sclerosis Patients: Latent Profile Analysis.
    Slavković S; Lazić M; Honan C; Nađ Č; Brkić-Jovanović N; Golubović Š
    Med Princ Pract; 2019; 28(4):373-379. PubMed ID: 30831571
    [TBL] [Abstract][Full Text] [Related]  

  • 110. A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
    Katsari M; Kasselimis DS; Giogkaraki E; Breza M; Evangelopoulos ME; Anagnostouli M; Andreadou E; Kilidireas C; Hotary A; Zalonis I; Koutsis G; Potagas C
    J Neurol; 2020 May; 267(5):1464-1475. PubMed ID: 32008073
    [TBL] [Abstract][Full Text] [Related]  

  • 111. New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients.
    Silveira F; Sánchez F; Miguez J; Contartese L; Gómez A; Patrucco L; Cristiano E; Rojas JI
    Neurol Res; 2020 Feb; 42(2):148-152. PubMed ID: 31959078
    [No Abstract]   [Full Text] [Related]  

  • 112. A useful annual review of cognition in relapsing MS is beyond most neurologists - NO.
    Langdon D
    Mult Scler; 2016 May; 22(6):728-30. PubMed ID: 27048311
    [No Abstract]   [Full Text] [Related]  

  • 113. A useful annual review of cognition in relapsing MS is beyond most neurologists - YES.
    McNicholas N; McGuigan C
    Mult Scler; 2016 May; 22(6):726-8. PubMed ID: 27048310
    [No Abstract]   [Full Text] [Related]  

  • 114. Are we ready to define cognitive worsening in MS? How different cutoffs detect future cognitive worsening after six years of follow-up.
    Damasceno A; Pimentel-Silva LR; Damasceno BP; Cendes F
    Mult Scler Relat Disord; 2023 Jan; 69():104402. PubMed ID: 36379184
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The broad impact of MS.
    Halper J
    Eur J Neurol; 2010 Mar; 17(3):341. PubMed ID: 19922455
    [No Abstract]   [Full Text] [Related]  

  • 116. Tracking successive Wallerian degenerations in a relapsing-remitting multiple sclerosis patient.
    Hannoun S; Durand-Dubief F; Roch JA; Sappey-Marinier D; Cotton F
    J Neuroradiol; 2016 Oct; 43(5):359-61. PubMed ID: 27502574
    [No Abstract]   [Full Text] [Related]  

  • 117. Serum BDNF levels are not reliable correlates of neurodegeneration in MS patients.
    Damasceno A; Damasceno BP; Cendes F; Damasceno A; Moraes AS; Farias A; dos Santos LM
    Mult Scler Relat Disord; 2015 Jan; 4(1):65-6. PubMed ID: 25787056
    [No Abstract]   [Full Text] [Related]  

  • 118. The evoked potentials score improves the identification of benign MS without cognitive impairment.
    Margaritella N; Mendozzi L; Tronci F; Colicino E; Garegnani M; Nemni R; Gilardi E; Pugnetti L
    Eur J Neurol; 2013 Oct; 20(10):1423-5. PubMed ID: 23293907
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    De Stefano N; Stromillo ML; Giorgio A; Battaglini M; Bartolozzi ML; Amato MP; Sormani MP
    Neurology; 2015 Nov; 85(19):1722-3. PubMed ID: 26468405
    [No Abstract]   [Full Text] [Related]  

  • 120. Primary care management of fatigue and relapses in RRMS.
    Oliver BJ
    Nurse Pract; 2009 Sep; 34(9):10-4. PubMed ID: 19713814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.